News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Client Alert March 3, 2026
When Should Companies Disclose Drug Safety Risks?
Our lawyers discuss a recent ruling highlighting when companies should disclose drug safety risks.
Firm News February 17, 2026
Gibson Dunn Advised Galecto on Public Offering of Common Stock
Gibson Dunn advised Galecto, Inc. on its public offering of common stock, which generated aggregate gross proceeds to the company of approximately $316 million.
Client Alert January 12, 2026
Life Sciences 2026 Outlook
The life sciences industry enters 2026 with a constructive set of tailwinds, following a second half of 2025 in which dealmaking activity showed clearer signs of normalization after a prolonged slowdown. While risks remain, particularly around geopolitics, trade policy, and regulatory priorities, the overall setup for 2026 is cautiously constructive, with improved visibility into execution pathways for well-positioned assets and platforms.
Firm News December 17, 2025
Gibson Dunn Advising Yarrow Bioscience on Merger with VYNE Therapeutics and Concurrent $200 Million Financings
Gibson Dunn is advising Yarrow Bioscience on its merger with VYNE Therapeutics and concurrent $200 million financings
Firm News December 3, 2025
Gibson Dunn Represented Mauser Packaging Solutions on $3.9 Billion Notes Exchange, $1 Billion Term Loan Financing, ABL Credit Facility Maturity Extension, and Cash Flow Revolver Maturity Extension
Gibson Dunn represented Mauser Packaging Solutions in an exchange offer of $2.6 billion in aggregate principal amount of their outstanding 7.875% Senior First Lien Notes due 2027 for newly issued 7.875% Senior First Lien Notes due 2030 and $1.3 billion in aggregate principal amount of their outstanding 9.25% Senior Secured Second Lien Notes due 2027 for newly issued 9.25% Senior Secured Second Lien Notes due 2030.
Webcasts November 20, 2025
Webcast: IPO Readiness Series: Crossover Rounds
Join us for a recorded presentation that provides an overview on crossover rounds leading up to an Initial Public Offering. …
Firm News November 12, 2025
Gibson Dunn Advising Damora Therapeutics on Sale to Galecto and on $285 Million Private Placement by Galecto
Gibson Dunn is advising privately held biotechnology company Damora Therapeutics, Inc. on its sale to Galecto, Inc.
Firm News October 28, 2025
Gibson Dunn Advised X4 Pharmaceuticals on Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Gibson Dunn advised X4 Pharmaceuticals on its public offering of common stock and full exercise of the underwriters’ option to purchase additional shares for gross proceeds of $155.3 million